Callan Family Office LLC Invests $768,000 in Boston Scientific Co. (NYSE:BSX)

Callan Family Office LLC acquired a new stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 8,598 shares of the medical equipment provider's stock, valued at approximately $768,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Adero Partners LLC lifted its position in Boston Scientific by 3.3% in the fourth quarter. Adero Partners LLC now owns 3,737 shares of the medical equipment provider's stock worth $334,000 after purchasing an additional 120 shares during the period. Grove Bank & Trust increased its stake in Boston Scientific by 4.4% in the fourth quarter. Grove Bank & Trust now owns 2,923 shares of the medical equipment provider's stock valued at $261,000 after acquiring an additional 122 shares during the period. PFG Investments LLC raised its position in Boston Scientific by 1.6% in the fourth quarter. PFG Investments LLC now owns 8,113 shares of the medical equipment provider's stock worth $725,000 after purchasing an additional 125 shares in the last quarter. Stonegate Investment Group LLC lifted its stake in Boston Scientific by 1.6% during the fourth quarter. Stonegate Investment Group LLC now owns 7,827 shares of the medical equipment provider's stock worth $699,000 after purchasing an additional 126 shares during the period. Finally, Ashton Thomas Securities LLC boosted its holdings in Boston Scientific by 1.3% during the third quarter. Ashton Thomas Securities LLC now owns 9,968 shares of the medical equipment provider's stock valued at $835,000 after purchasing an additional 129 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling at Boston Scientific

In related news, EVP Jeffrey B. Mirviss sold 4,675 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $104.25, for a total transaction of $487,368.75. Following the completion of the transaction, the executive vice president now owns 28,454 shares in the company, valued at approximately $2,966,329.50. This represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP John Bradley Sorenson sold 4,119 shares of Boston Scientific stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total transaction of $370,792.38. Following the completion of the sale, the executive vice president now owns 35,319 shares in the company, valued at $3,179,416.38. The trade was a 10.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 137,302 shares of company stock worth $14,319,269. Corporate insiders own 0.50% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft raised Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 target price for the company in a report on Friday, January 10th. UBS Group lifted their price objective on Boston Scientific from $105.00 to $130.00 and gave the company a "buy" rating in a report on Friday, February 7th. Royal Bank of Canada upped their target price on shares of Boston Scientific from $105.00 to $116.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. Needham & Company LLC reissued a "hold" rating on shares of Boston Scientific in a report on Monday, March 3rd. Finally, Raymond James upped their price objective on shares of Boston Scientific from $119.00 to $122.00 and gave the stock a "strong-buy" rating in a research note on Thursday, February 6th. Two research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $108.91.

Boston Scientific Trading Up 0.9 %

BSX stock traded up $0.90 during midday trading on Wednesday, hitting $96.42. 8,789,982 shares of the company's stock were exchanged, compared to its average volume of 5,775,966. Boston Scientific Co. has a one year low of $65.52 and a one year high of $107.17. The stock's fifty day moving average price is $100.66 and its 200-day moving average price is $91.49. The company has a market cap of $142.29 billion, a PE ratio of 77.14, a price-to-earnings-growth ratio of 2.79 and a beta of 0.77. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Research analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.